Genmab Cancer Drug Wins Fuel a Big Shift to Owning More Medicines

Introduction. A drug company has good news about a cancer medicine. Its test results were strong. Its shares jumped 12%. Now the company wants a big change. It wants to own more of its own medicines. That means less sharing with other companies. What Happened. Genmab is a company in Denmark. It makes medicines for cancer. Its medicine is called petosemtamab. It is used for head and neck cancer. In a test, it was used with another medicine called Keytruda. The test showed a 50% lower risk of death. That was compared to Keytruda alone. The risk of the cancer getting worse fell 46%. Genmab shares jumped 12% on the news. It was the biggest rise in three months. Key Figures. Shares rose 12%. Risk of death fell 50%. Risk of cancer getting worse fell 46%. Genmab shares are up about 38% this year. Genmab has a market value of about $30 billion. Market value means what all its shares are worth together. Why It Happened. Genmab had a plan. It wanted to own more of its own medicines. It used to share more with partners. Now it wants to keep more for itself. It bought a company called Merus. That gave it full control of petosemtamab. It also bought another drug, called rinatabart sesutecan. It paid $1.7 billion for it. That drug is for a type of ovarian cancer. Why It Matters. Cancer medicines can help many people. Good test results can mean hope for patients. They can also mean more money for the company. That money can fund more tests. What Happens Next. Genmab will ask regulators to approve the medicine. Regulators are people who check if a medicine is safe. Genmab will also test its other new drugs. Final Thoughts. A strong test can change a company. Genmab now wants to stand more on its own. It will be watched closely in the next year. Read more on this blog: Bill Ackman Warns the Stock Market Looks Like a Casino, https://financewithrohan.com/2026/11/03/bill-ackman-warns-the-stock-market-looks-like-a-casino/ Disclaimer: This article is for educational and informational purposes only and does not constitute financial advice. Sources: CNBC, Genmab cancer drug wins fuel shift to owning more medicines, https://www.cnbc.com/2026/11/03/genmab-cancer-drugs-petosemtamab.html ; Genmab, Genmab and Pfizer announce positive topline results for petosemtamab in head and neck cancer, https://ir.genmab.com/news-releases/news-release-details/genmab-and-pfizer-announce-positive-topline-results An Example. Think of a team that used to share a toy. Now it wants its own toy. It can decide how to use it. It can also keep more of the reward. That is what Genmab wants to do with its medicines.